These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20211900)

  • 1. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.
    Bulitta JB; Yang JC; Yohonn L; Ly NS; Brown SV; D'Hondt RE; Jusko WJ; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2010 May; 54(5):2051-62. PubMed ID: 20211900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.
    Bulitta JB; Ly NS; Yang JC; Forrest A; Jusko WJ; Tsuji BT
    Antimicrob Agents Chemother; 2009 Jan; 53(1):46-56. PubMed ID: 18852268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
    Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
    J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
    Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.
    Bulitta JB; Ly NS; Landersdorfer CB; Wanigaratne NA; Velkov T; Yadav R; Oliver A; Martin L; Shin BS; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2315-27. PubMed ID: 25645838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates.
    Vila-Farrés X; Callarisa AE; Gu X; Savage PB; Giralt E; Vila J
    Int J Antimicrob Agents; 2015 Nov; 46(5):568-71. PubMed ID: 26395218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
    Kolpen M; Appeldorff CF; Brandt S; Mousavi N; Kragh KN; Aydogan S; Uppal HA; Bjarnsholt T; Ciofu O; Høiby N; Jensen PØ
    Pathog Dis; 2016 Feb; 74(1):ftv086. PubMed ID: 26458402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
    Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bergen PJ; Li J; Nation RL; Turnidge JD; Coulthard K; Milne RW
    J Antimicrob Chemother; 2008 Mar; 61(3):636-42. PubMed ID: 18227094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
    Khan DD; Friberg LE; Nielsen EI
    J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Li J; Turnidge J; Milne R; Nation RL; Coulthard K
    Antimicrob Agents Chemother; 2001 Mar; 45(3):781-5. PubMed ID: 11181360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Gunderson BW; Ibrahim KH; Hovde LB; Fromm TL; Reed MD; Rotschafer JC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):905-9. PubMed ID: 12604520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Güzel CB; Gerçeker AA
    Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.